Stocks and Investing
Stocks and Investing
Mon, June 27, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Derek Archila Initiated (BPMC) at Sell and Held Target at $40 on, Jun 27th, 2022
Derek Archila of Wells Fargo, Initiated "Blueprint Medicines Corporation" (BPMC) at Sell and Held Target at $40 on, Jun 27th, 2022.
Derek has made no other calls on BPMC in the last 4 months.
There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 3 agree with Derek's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $65 on, Tuesday, June 14th, 2022
- Andrew Berens of "SVB Leerink" Maintained at Hold with Decreased Target to $60 on, Monday, June 13th, 2022
- Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022
These are the ratings of the 3 analyists that currently disagree with Derek
- David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
- Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022
- Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022
Contributing Sources